Investigators conducted a systematic review of studies published between January 1, 2020 and January 29, 2021 that estimated the prevalence of major depressive disorder and anxiety disorders during the COVID-19 pandemic.
Investigators report the findings from a study assessing the impact of insomnia on clinical outcomes in patients with major depressive disorder.
Examining the potential shared genetic liability of sleep deficits and cannabis use behaviors using multiple genomic methods.
This study highlights the importance of transdiagnostic approaches to psychiatry.
While the relationship between current mood state and cognitive impairment is unclear, more severe depression has been linked to greater impairment.
Overall, in all patients with MDD, sleep ultradian cycle number was positively associated with REMS percentage, REMS duration, and REMS/NREMS ratio and negatively associated with REM latency.
The study provides strong evidence for the utility of resting-state fMRI measures in predicting the development of attentional or mood disorders in children.
The risk factors for tardive dyskinesia in patients taking antipsychotics include age, comorbid diagnoses, and high medication dosages.
Cognitive behavioral therapy may improve a diverse array of depressive symptoms in patients with Parkinson disease.
Multimarker inflammatory biosignatures are expected to facilitate diagnosis and predict treatment outcomes for various central nervous system disorders, particularly Alzheimer disease and major depressive disorder.